Who Exports Exemestane from India — 87 Suppliers Behind a $14.5M Market
India's exemestane export market is supplied by 87 active exporters who collectively shipped $14.5M across 1,533 shipments. INTAS PHARMACEUTICALS LIMITED leads with a 31.1% market share, followed by EUGIA PHARMA SPECIALITIES LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED. The top 5 suppliers together control 78.1% of total export value, reflecting a concentrated market structure.
Top Exemestane Exporters from India — Ranked by Export Value
INTAS PHARMACEUTICALS LIMITED is the leading exemestane exporter from India, holding a 31.1% share of the $14.5M market across 1,533 shipments from 87 exporters. The top 5 suppliers — INTAS PHARMACEUTICALS LIMITED, EUGIA PHARMA SPECIALITIES LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, MSN LABORATORIES PRIVATE LIMITED, CIPLA LIMITED — collectively control 78.1% of total export value, indicating a highly concentrated market. Individual shares are: INTAS PHARMACEUTICALS LIMITED (31.1%), EUGIA PHARMA SPECIALITIES LIMITED (15.4%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (12.3%), MSN LABORATORIES PRIVATE LIMITED (12.0%), CIPLA LIMITED (7.3%).
Top Exemestane Exporters from India
Ranked by export value · 87 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | INTAS PHARMACEUTICALS LIMITED PHARMA DRUGS & MEDI EXEMESTANE 25MG 10X1PHARMA DRUG&MED:EXEMESTANE 25MG 10X10T GEXEMESTANE TABLETS 25MG ,BAT | $4.5M | 21 | 31.1% |
| 2 | EUGIA PHARMA SPECIALITIES LIMITED EXEMESTANE TABLETS 25 MG - 1 X 30.EXEMESTANE TABLETS 25 MGEXEMESTANE TABLETS 25 MG (EXEMESTANE TAB | $2.2M | 1 | 15.4% |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED EXEMESTANE TABLETS 25MG ,BATEXEMESTANE TABLETS 25MG EXEMESTANE PACK:3X10EXEMESTANE TABLETS USP 25MG PACK SIZE: 1X 30S | $1.8M | 4 | 12.3% |
| 4 | MSN LABORATORIES PRIVATE LIMITED EXEMESTANE TABLETS 25 MG - 1 X 30.EXEMESTANE TABLETS 25 MGEXEMESTANE TABLETS 25 MG (EXEMESTANE TAB | $1.7M | 1 | 12.0% |
| 5 | CIPLA LIMITED EXEMESTANE TABLETS 25 MG - 1 X 30.EXEMESTANE TABLETS 25 MGEXEMESTANE TABLETS USP 25MG PACK SIZE: 1X 30S | $1.1M | 3 | 7.3% |
| 6 | TITAN LABORATORIES PRIVATE LIMITED EXEMESTANE 25MG FILM COATED TABLETSEXEMESTANE TABLETS 25 MG 31528X03X10 BOXES 945840 TABLETS | $725.3K | 1 | 5.0% |
| 7 | ZYDUS LIFESCIENCES LIMITED EXEMESTANE TABLETS 25 MG - 1 X 30.EXEMESTANE TABLETS 25 MGEXEMESTANE TABLETS 25 MG (EXEMESTANE TAB | $582.2K | 1 | 4.0% |
| 8 | CADILA HEALTHCARE LIMITED EXEMESTANE TABLETS 25 MG - 1 X 30.EXEMESTANE TABLETS 25 MGEXEMESTANE TABLETS 25 MG (EXEMESTANE TAB | $372.1K | 1 | 2.6% |
| 9 | INTAS PHARMACEUTICALS LTD PHARMA DRUGS & MEDI EXEMESTANE 25MG 10X1PHARMA DRUG&MED:EXEMESTANE 25MG 10X10T GEXEMESTANE TABLETS 25MG ,BAT | $355.9K | 4 | 2.5% |
| 10 | JODAS EXPOIM PRIVATE LIMITED | $136.6K | 1 | 0.9% |
| 11 | CELON LABORATORIES PRIVATE LIMITED | $119.7K | 4 | 0.8% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Exemestane exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Intas Pharmaceuticals Limited | Warning Letter issued in | Yes | Yes | Not verified | Received FDA Warning Letter in November 2023 for CGMP violations; holds WHO-GMP |
| Sun Pharmaceutical Industries Limited | Warning Letter issued in | Yes | Yes | Not verified | Received FDA Warning Letter in June 2024; holds WHO-GMP and EU GMP certification |
| Cipla Limited | Approved | Yes | Yes | Multiple | FDA-approved with multiple ANDAs; holds WHO-GMP and EU GMP certifications. |
| Zydus Lifesciences Limited | Warning Letter issued in | Yes | Yes | Not verified | Received FDA Warning Letter in August 2024; holds WHO-GMP and EU GMP certificati |
| Eugia Pharma Specialities Limited | Warning Letter issued in | Unknown | Unknown | Not verified | Received FDA Warning Letter in August 2024; WHO-GMP and EU GMP statuses are unkn |
| MSN Laboratories Private Limited | Approved | Yes | Yes | Multiple | FDA-approved with multiple ANDAs; holds WHO-GMP and EU GMP certifications. |
| Cadila Healthcare Limited | Approved | Yes | Yes | Multiple | FDA-approved with multiple ANDAs; holds WHO-GMP and EU GMP certifications. |
| Intas Pharmaceuticals Ltd | Warning Letter issued in | Yes | Yes | Not verified | Received FDA Warning Letter in November 2023 for CGMP violations; holds WHO-GMP |
| Jodas Expoim Private Limited | Approved | Yes | Yes | Multiple | FDA-approved with multiple ANDAs; holds WHO-GMP and EU GMP certifications. |
TransData Nexus reviewed the regulatory standing of 9 leading Exemestane exporters from India. 4 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 8 are EU GMP compliant. 5 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Exemestane sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes over 40% of the country's bulk drug production. The city hosts a robust ecosystem of pharmaceutical companies specializing in active pharmaceutical ingredients (APIs) and bulk drug manufacturing. Notable firms such as Dr. Reddy's Laboratories and Aurobindo Pharma have established extensive operations in the region, leveraging Hyderabad's strategic advantages in infrastructure and skilled workforce. The presence of Hyderabad Pharma City, recognized as a National Investment Manufacturing Zone, further underscores the city's pivotal role in India's pharmaceutical landscape.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat has emerged as a significant hub for pharmaceutical formulations. This region is home to leading companies like Alembic Pharmaceuticals, headquartered in Vadodara, which specializes in the production of formulations across various therapeutic areas. The state's pharmaceutical sector is characterized by a strong focus on innovation and quality, supported by a well-established industrial infrastructure and a skilled workforce. The presence of multiple pharmaceutical clusters dedicated to formulations and biogenerics highlights the region's strategic importance in the pharmaceutical industry. (mediaindia.eu)
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for India's pharmaceutical products. Mumbai, being a major port city, facilitates the efficient export of pharmaceuticals to global markets. The region hosts several pharmaceutical manufacturing units that produce a wide range of formulations and APIs. Companies in this area benefit from the proximity to international shipping routes, well-developed logistics infrastructure, and access to a large talent pool, making it a strategic location for pharmaceutical exports.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has become a prominent pharmaceutical manufacturing zone, primarily due to favorable tax incentives offered by the government. This area attracts numerous pharmaceutical companies seeking cost-effective production facilities. The region's infrastructure supports large-scale manufacturing, and the tax benefits have led to significant investments in pharmaceutical production, contributing to the overall growth of India's pharmaceutical exports.
5Sourcing Recommendations
- Diversify Supplier Base: While the top five exporters dominate the Exemestane market, engaging with a broader range of suppliers can mitigate risks associated with supply chain disruptions.
- Leverage Regional Strengths: Utilize Hyderabad's expertise in bulk drug production for sourcing APIs and consider Ahmedabad-Vadodara for high-quality formulations to optimize the supply chain.
- Optimize Logistics: Capitalize on the Mumbai-Thane-Raigad region's export infrastructure to ensure timely and efficient delivery of pharmaceutical products to international markets.
- Evaluate Cost Benefits: Assess the financial advantages of manufacturing in tax incentive zones like Baddi-Nalagarh to reduce production costs without compromising quality.
By strategically sourcing from these key pharmaceutical clusters, companies can enhance their supply chain resilience and competitiveness in the global Exemestane market.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Exemestane exporters from India
Sun Pharmaceutical Industries Limited — Sun Pharma acquires Checkpoint Therapeutics for $355 million
In March 2025, Sun Pharma announced the acquisition of Checkpoint Therapeutics, a Waltham, Massachusetts-based company specializing in immunotherapy and targeted oncology treatments, for $355 million. - IMPACT: This acquisition is expected to enhance Sun Pharma's oncology portfolio, potentially influencing its strategic focus and resource allocation, which may indirectly affect its Exemestane export activities.
Impact: This acquisition is expected to enhance Sun Pharma's oncology portfolio, potentially influencing its strategic focus and resource allocation, which may indirectly affect its Exemestane export activities.
Common Questions — Exemestane Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which exemestane supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, INTAS PHARMACEUTICALS LIMITED leads with 260 recorded shipments worth $4.5M. EUGIA PHARMA SPECIALITIES LIMITED (27 shipments) and SUN PHARMACEUTICAL INDUSTRIES LIMITED (18 shipments) are also established high-volume exporters.
Q How many exemestane manufacturers are there in India?
India has 87 active exemestane exporters with a combined export market of $14.5M across 1,533 shipments to 57 countries. The top 5 suppliers hold 78.1% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for exemestane from India?
Average FOB unit price: $47.52 per unit, ranging from $0.01 to $6892.13. Average shipment value: $9.4K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 87 verified Indian exporters of Exemestane ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,533 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 57 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,533 Verified Shipments
87 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists